Bednarek Kinga, Kostrzewska-Poczekaj Magdalena, Szaumkessel Marcin, Kiwerska Katarzyna, Paczkowska Julia, Byzia Ewa, Ustaszewski Adam, Janiszewska Joanna, Bartochowska Anna, Grenman Reidar, Wierzbicka Malgorzata, Szyfter Krzysztof, Giefing Maciej, Jarmuz-Szymczak Malgorzata
Institute of Human Genetics, Polish Academy of Sciences Poznan, Poland.
Department of Tumor Pathology, Greater Poland Cancer Center Poznan, Poland.
Am J Cancer Res. 2018 Jul 1;8(7):1249-1261. eCollection 2018.
We have turned our attention to gene, already described as deregulated in various types of cancer. By using the expression microarrays performed on the set of 16 laryngeal squamous cell carcinoma (LSCC) samples: 11 cell lines and 5 primary tumors we have shown downregulation of gene as compared to non cancer controls from head and neck region. gene downregulation, further confirmed by quantitative PCR on 25 LSCC cell lines, was observed in cell lines derived from recurrent tumors in comparison to controls. A significant gene downregulation was observed in cell lines derived from advanced, high grade tumors in comparison to controls. Intrigued by the recurrent transcriptional loss of we searched for the mechanism potentially responsible for its downregulation and hence we analyzed DNA copy number changes (a-CGH), promoter DNA methylation status and occurrence of gene mutations (). Neither the analysis of gene copy number, nor the mutation screen has shown recurrent deletions or mutations, that could contribute to the observed downregulation of the gene. However, by using bisulfite pyrosequencing, we have shown DNA hypermethylation (mean DNA methylation > 78%) of promoter region in 9/25 (36%) LSCC cell lines. Importantly, the 5-aza-2-deoxycytidine-induced inhibition of DNA methylation resulted in restoration of expression in the two LSCC cell lines on mRNA level. In summary, we have shown that recurrent downregulation of in LSCC is dependent on the gene's promoter DNA methylation and is observed predominantly in large, poorly differentiated tumors and recurrences.
我们已将注意力转向一个已被描述为在各种类型癌症中失调的基因。通过对16个喉鳞状细胞癌(LSCC)样本(11个细胞系和5个原发性肿瘤)进行表达微阵列分析,我们发现与头颈部区域的非癌对照相比,该基因表达下调。通过对25个LSCC细胞系进行定量PCR进一步证实,与对照相比,在复发肿瘤来源的细胞系中观察到该基因下调。与对照相比,在晚期、高分级肿瘤来源的细胞系中观察到该基因显著下调。受该基因反复转录缺失的影响,我们寻找可能导致其下调的机制,因此我们分析了DNA拷贝数变化(a-CGH)、启动子DNA甲基化状态和基因突变情况()。基因拷贝数分析和突变筛查均未显示出可能导致观察到的基因下调的反复缺失或突变。然而,通过亚硫酸氢盐焦磷酸测序,我们发现9/25(36%)的LSCC细胞系中该基因启动子区域存在DNA高甲基化(平均DNA甲基化>78%)。重要的是,5-氮杂-2'-脱氧胞苷诱导的DNA甲基化抑制导致两个LSCC细胞系中该基因在mRNA水平上的表达恢复。总之,我们已表明LSCC中该基因的反复下调依赖于该基因启动子DNA甲基化,且主要在大的、低分化肿瘤和复发肿瘤中观察到。